Treats Gastroesophageal Reflux Disease (GERD) with erosive esophagitis (EE). ANDA 203349, held by Gland. Esomeprazole Sodium.
As of Nov 16, 2026, ANDA 203349 (Esomeprazole Sodium), held by Gland, was first approved by FDA on Apr 1, 2020, with 2 approved supplements and 0 published complete response letters.
Esomeprazole sodium for injection is a proton pump inhibitor (PPI) indicated for the:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 1, 2020 | Original application | Approved | None posted |
| Esomeprazole SodiumEQ 20MG BASE/VIAL · injectable;intravenous | Esomeprazole Sodium | Rx |
| Esomeprazole SodiumEQ 40MG BASE/VIAL · injectable;intravenous | Esomeprazole Sodium | Rx |
| Mar 8, 2023 | Supplement 2Labeling · Standard review | Approved | None posted |
| Mar 8, 2023 | Supplement 3Labeling · Standard review | Approved | None posted |
| Apr 1, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters